Tarsus Pharmaceuticals, a commercial-stage biopharmaceutical company focused on eye care, reported strong net product sales for its first-to-market FDA-approved therapy XDEMVY in Q2 2026. The company is expanding its pipeline through internal development of novel treatments in ocular and infectious diseases as well as acquisitions like IRenix and Alkeus to broaden therapeutic reach. Despite continued net losses resulting from substantial R&D and SG&A investments, Tarsus demonstrates solid liquidity and access to capital, positioning it for sustained commercialization efforts. Challenges remain in diversifying revenue beyond the single approved product and managing regulatory, reimbursement, and competition risks.